About us

About Insypr Therapeutics

Inspyr Therapeutics, Inc. is an integrated clinical-stage biopharmaceutical company focused on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer based on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark, Inspyr has a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. The pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

The company involves in the discovery and development of pro-drug cancer therapeutics. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its pro-drug development candidates include G-202, which is in Phase I clinical trials and targets the blood vessels of various solid tumors; and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for the treatment of prostate cancer.